Findings from pediatric trials showed left ventricular opacification with Definity was successful and provided important information to guide patient management. The Food and Drug Administration (FDA) ...
BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow ® disease ...
Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
Lantheus Holdings, Inc. LNTH recently announced that the FDA has approved the supplemental new drug application for DEFINITY (Perflutren Lipid Microsphere) as an ultrasound-enhancing agent for use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback